Supernus Pharmaceuticals, Inc. (SUPN): Price and Financial Metrics


Supernus Pharmaceuticals, Inc. (SUPN): $37.51

0.49 (+1.32%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SUPN POWR Grades

  • SUPN scores best on the Value dimension, with a Value rank ahead of 96.8% of US stocks.
  • The strongest trend for SUPN is in Momentum, which has been heading up over the past 179 days.
  • SUPN ranks lowest in Momentum; there it ranks in the 24th percentile.

SUPN Stock Summary

  • SUPN's current price/earnings ratio is 51.08, which is higher than 88.96% of US stocks with positive earnings.
  • Over the past twelve months, SUPN has reported earnings growth of -70.94%, putting it ahead of only 18.79% of US stocks in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SUPN comes in at 6.61% -- higher than that of 78.29% of stocks in our set.
  • Stocks that are quantitatively similar to SUPN, based on their financial statements, market capitalization, and price volatility, are MTRN, MMSI, PLPC, AIN, and GAMB.
  • Visit SUPN's SEC page to see the company's official filings. To visit the company's web site, go to www.supernus.com.

SUPN Valuation Summary

  • SUPN's price/earnings ratio is 50.5; this is 117.67% higher than that of the median Healthcare stock.
  • Over the past 129 months, SUPN's price/sales ratio has gone down 163.7.

Below are key valuation metrics over time for SUPN.

Stock Date P/S P/B P/E EV/EBIT
SUPN 2022-11-25 2.9 2.2 50.5 57.1
SUPN 2022-11-23 2.9 2.2 50.0 56.6
SUPN 2022-11-22 2.9 2.2 50.1 56.7
SUPN 2022-11-21 2.8 2.2 49.7 56.3
SUPN 2022-11-18 2.8 2.2 49.5 56.1
SUPN 2022-11-17 2.8 2.2 48.9 55.5

SUPN Growth Metrics

    Its 3 year net cashflow from operations growth rate is now at -29.38%.
  • Its 2 year price growth rate is now at 13.03%.
  • Its 5 year net cashflow from operations growth rate is now at 78.19%.
SUPN's revenue has moved up $88,007,000 over the prior 15 months.

The table below shows SUPN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 658.96 138.025 37.672
2022-06-30 630.071 120.074 57.485
2022-03-31 601.349 95.229 73.346
2021-12-31 579.775 127.127 53.424
2021-09-30 564.282 110.297 81.75
2021-06-30 570.953 120.006 100.185

SUPN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SUPN has a Quality Grade of B, ranking ahead of 91.1% of graded US stocks.
  • SUPN's asset turnover comes in at 0.375 -- ranking 128th of 682 Pharmaceutical Products stocks.
  • RETA, INVA, and PTCT are the stocks whose asset turnover ratios are most correlated with SUPN.

The table below shows SUPN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.375 0.860 0.164
2021-03-31 0.370 0.886 0.187
2020-12-31 0.366 0.899 0.196
2020-09-30 0.357 0.920 0.201
2020-06-30 0.343 0.949 0.173
2020-03-31 0.356 0.957 0.155

SUPN Price Target

For more insight on analysts targets of SUPN, see our SUPN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $35.00 Average Broker Recommendation 1.67 (Moderate Buy)

SUPN Stock Price Chart Interactive Chart >

Price chart for SUPN

SUPN Price/Volume Stats

Current price $37.51 52-week high $37.89
Prev. close $37.02 52-week low $24.95
Day low $36.11 Volume 533,400
Day high $37.89 Avg. volume 411,691
50-day MA $34.01 Dividend yield N/A
200-day MA $31.50 Market Cap 2.03B

Supernus Pharmaceuticals, Inc. (SUPN) Company Bio


Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The company was founded in 2005 and is based in Rockville, Maryland.


SUPN Latest News Stream


Event/Time News Detail
Loading, please wait...

SUPN Latest Social Stream


Loading social stream, please wait...

View Full SUPN Social Stream

Latest SUPN News From Around the Web

Below are the latest news stories about SUPERNUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SUPN as an investment opportunity.

Supernus to Present at the Piper Sandler 34th Annual Healthcare Conference

ROCKVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat, as well as host investor meetings, at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022, at 10:30 a.m. ET. The co

Yahoo | November 22, 2022

Supernus Pharmaceuticals Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags

Supernus Pharmaceuticals ( NASDAQ:SUPN ) Third Quarter 2022 Results Key Financial Results Revenue: US$177.4m (up 20...

Yahoo | November 11, 2022

Supernus Pharmaceuticals (SUPN) Misses Q3 Earnings Estimates

Supernus (SUPN) delivered earnings and revenue surprises of -90.63% and 2.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 9, 2022

Supernus to Present at Two November Healthcare Conferences

ROCKVILLE, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will present a Company overview and update, as well as host investor meetings, at the following November conferences: Stifel 2022 Healthcare ConferenceDate: Tuesday, November 15, 202

Yahoo | November 8, 2022

Supernus Announces Third Quarter 2022 Financial Results

Third quarter 2022 total revenues of $177.4 million, a 19% increase compared to third quarter 2021Increasing full year 2022 operating earnings guidance to $35 million to $45 million, from $20 million to $40 million previouslyIncreasing full year 2022 total revenues guidance to $650 million to $680 million, from $640 million to $680 million previouslyQelbree® continued its growth trajectory, with 94,328 prescriptions in third quarter 2022, a 50% increase compared to second quarter 2022Third quart

Yahoo | November 8, 2022

Read More 'SUPN' Stories Here

SUPN Price Returns

1-mo 9.33%
3-mo 9.07%
6-mo 34.11%
1-year 23.43%
3-year 63.73%
5-year 0.97%
YTD 28.64%
2021 15.90%
2020 6.07%
2019 -28.60%
2018 -16.64%
2017 57.82%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8323 seconds.